Paper List

Open Access Academic Papers from Research Square

4 results found
Research Article under-review

Reporting quality of randomized, controlled trials evaluating immunotherapy for ovarian cancer: cross-sectional study

Mingwei Liang, Xinxin Zhang, Wenli Wu, Ruijie Yu, Zhiruo Liao, Qianqian Cao, Xiyue Su, Jia lu, Jihua Wang

Background Incorporating immunotherapy effectively remains a priority in therapeutic research of ovarian cancer, making it essential to conduct and report randomized, controlled trials (RCTs) with hig...

BMC Cancer 2026-04-23 rs-9020902
CONSORT statement ovarian cancer immunotherapy reporting quality randomized controlled trial
View Original PDF
Research Article under-review

Serum Interleukin-6 and TNF-α level are useful biomarker to predict the efficacy of chemotherapy combined with immunotherapy in locally advanced Non-Small Cell Lung Cancer

Xin Zhang, Houjun Jiang, Cheng Chen, Jianhua Ma

Objective To investigates the role of serum interleukin-6 (IL-6) and tumor necrosis factor-α(TNF-α) levels as prognostic biomarkers in patients receiving First-Line Platinum-Based Chemotherapy Combine...

Journal of Cancer Research and Clinical Oncology 2026-04-22 rs-9242248
Non-small cell lung cancer Immunotherapy platinum-based chemotherapy Efficacy prediction Interleukin-6 Tumor necrosis factor-α
View Original PDF
Research Article under-review

Tumor Infiltrating Lymphocytes (TILs) as a Predictive Marker of Pathological Complete Response (pCR) in a Diverse Patient Population with Early Triple Negative Breast Cancer (TNBC) Treated with Neoadjuvant Real-World KEYNOTE-522 Regimen

Riya Albert, Joshua Thomas, Navid Sadeghi, Sangeetha Reddy, Glenda Delgado, Heather McArthur, Samira Syed, Deborah Farr, Nisha Unni

Introduction Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by poor prognosis. Based on the KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy has become the s...

Breast Cancer Research and Treatment 2026-04-21 rs-9096569
tumor-infiltrating lymphocytes triple-negative breast cancer neoadjuvant therapy immunotherapy pathological complete response
View Original PDF
Research Article posted

A conserved 8-gene epithelial barrier signature spatially quantifies immune exclusion across cancers and predicts immunotherapy outcome independent of HPV status

Tan Haosheng, Yu Dapeng, Jiao lianghe

Background Tumor epithelial barriers physically impede immune cell infiltration, causing immune exclusion and resistance to immune checkpoint inhibitors (ICIs). However, a simple, spatially quantifiab...

Research Square 2026-04-21 rs-9472940
epithelial barrier signature spatial transcriptomics immune exclusion immunotherapy outcome
View Original PDF
Back to Top
Home
Browse
Submit
About
0.036471s